{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-038539","form_type":"8-K","ticker":"LBRX","cik":"0001691082","company_name":"LB PHARMACEUTICALS INC","filed_at":"2026-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.902618+00:00","generated_at":"2026-05-16T04:28:43.379852+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"LB Pharmaceuticals raises $100M in private placement; Phase 2 MDD trial for LB-102 starts early 2027","bullets":["Gross proceeds ~$100M from sale of 3.31M shares and 1.42M pre-funded warrants at $21.17/share.","Investors include Balyasny, Caligan, Commodore, Deep Track, Nantahala, Pivotal, Spruce Street, TCGX, Trails Edge.","Net proceeds to fund Phase 2 trial of LB-102 as adjunctive MDD treatment and for working capital.","Phase 2 trial: 380 patients, 50 sites U.S./Europe, randomized 1:1 vs placebo, primary endpoint MADRS-10 at week 6.","Trial to start early 2027; topline results expected first half 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-038539","json":"https://secwatch.observer/filing/0001193125-26-038539.json","markdown":"https://secwatch.observer/filing/0001193125-26-038539.md","text":"https://secwatch.observer/filing/0001193125-26-038539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/0001193125-26-038539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/d943290d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:28:43.379852+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf359c8a80453b5b741abb855145098a9fdb8de7","claim":"LB PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain investors valued at approximately $100.0 million (effective 2026-02-04).","evidence_excerpt":"On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,417,107 shares of Common Stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526038539/0001193125-26-038539-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $100.0 million"},{"label":"Effective","value":"2026-02-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}